[go: up one dir, main page]

MX2010006854A - Biomarcadores para sensibilidad a terapia anti-receptor-1 del factor de crecimiento tipo insulina. - Google Patents

Biomarcadores para sensibilidad a terapia anti-receptor-1 del factor de crecimiento tipo insulina.

Info

Publication number
MX2010006854A
MX2010006854A MX2010006854A MX2010006854A MX2010006854A MX 2010006854 A MX2010006854 A MX 2010006854A MX 2010006854 A MX2010006854 A MX 2010006854A MX 2010006854 A MX2010006854 A MX 2010006854A MX 2010006854 A MX2010006854 A MX 2010006854A
Authority
MX
Mexico
Prior art keywords
biomarkers
sensitivity
methods
igf1r
therapy
Prior art date
Application number
MX2010006854A
Other languages
English (en)
Inventor
Yan Wang
Yaolin Wang
Ming Liu
Cynthia Seidel-Dugan
Diane Levitan
Wei Ding
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2010006854A publication Critical patent/MX2010006854A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q99/00—Subject matter not provided for in other groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Theoretical Computer Science (AREA)
  • Microbiology (AREA)
  • Business, Economics & Management (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • General Business, Economics & Management (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención proporciona, por ejemplo, métodos para determinar convenientemente si una condición cancerosa en un sujeto será sensible a un inhibidor de IGF1R; la invención incluye métodos de selección de paciente y métodos de tratamiento.
MX2010006854A 2007-12-18 2008-12-17 Biomarcadores para sensibilidad a terapia anti-receptor-1 del factor de crecimiento tipo insulina. MX2010006854A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1455607P 2007-12-18 2007-12-18
US1593807P 2007-12-21 2007-12-21
US2290908P 2008-01-23 2008-01-23
PCT/US2008/087240 WO2009079587A2 (en) 2007-12-18 2008-12-17 Biomarkers for sensitivity to anti-igf1r therapy

Publications (1)

Publication Number Publication Date
MX2010006854A true MX2010006854A (es) 2010-09-09

Family

ID=40796133

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010006854A MX2010006854A (es) 2007-12-18 2008-12-17 Biomarcadores para sensibilidad a terapia anti-receptor-1 del factor de crecimiento tipo insulina.

Country Status (6)

Country Link
US (1) US20110091524A1 (es)
EP (1) EP2247757A2 (es)
JP (2) JP2011505873A (es)
CA (1) CA2709827A1 (es)
MX (1) MX2010006854A (es)
WO (1) WO2009079587A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2405566C2 (ru) 2005-02-03 2010-12-10 Дзе Дженерал Хоспитал Корпорейшн Способ лечения рака, устойчивого к гефитинибу
AU2006311877A1 (en) 2005-11-04 2007-05-18 Wyeth Llc Antineoplastic combinations with mTOR inhibitor, herceptin, and/orHKI-272
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
NZ616613A (en) 2008-06-17 2015-05-29 Wyeth Llc Antineoplastic combinations containing hki-272 and vinorelbine
LT2326329T (lt) 2008-08-04 2017-05-25 Wyeth Llc 4-anilin-3-cianochinolinų ir kapecitabino antinavikiniai deriniai
UY32317A (es) 2008-12-12 2010-07-30 Boehringer Ingelheim Int Anticuerpos anti-igf
KR20180056796A (ko) 2009-04-06 2018-05-29 와이어쓰 엘엘씨 네라티닙을 이용한 유방암의 치료법
EA026815B1 (ru) * 2009-11-18 2017-05-31 Хелсинн Хелткэа Са Пероральная лекарственная форма, содержащая палоносетрон и нетупитант, капсульная лекарственная форма, способ лечения тошноты и рвоты
US9110082B2 (en) 2009-11-30 2015-08-18 Merck Sharp & Dohme Corp. Methods for the identification and treatment of patients sensitive to anti IGF-1R inhibition therapy
US20140037642A1 (en) 2011-02-02 2014-02-06 Amgen Inc. Methods and compositions relating to inhibition of igf-1r
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
WO2012175481A1 (en) * 2011-06-20 2012-12-27 Institut Curie Compositions and methods for treating leukemia
US20150258170A1 (en) * 2012-10-10 2015-09-17 The Trustees Of Columbia University In The City Of New York Diagnosis and Treatment of SMA and SMN Deficiency
WO2014074847A1 (en) 2012-11-09 2014-05-15 The Johns Hopkins University A genetic assay to determine prognosis in polycythemia vera patients
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
ES2871418T3 (es) 2013-08-28 2021-10-28 Abbvie Stemcentrx Llc Composiciones y métodos de conjugación de anticuerpos específicos de sitio
PE20161209A1 (es) 2014-02-21 2016-11-10 Abbvie Stemcentrx Llc Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma
WO2016031816A1 (ja) * 2014-08-26 2016-03-03 学校法人慶應義塾 抗がん剤の感受性の判定マーカー
US20170372347A1 (en) * 2016-06-22 2017-12-28 International Business Machines Corporation Sequence-based marketing attribution model for customer journeys
AU2018315434A1 (en) * 2017-08-10 2020-04-02 The Institute Of Cancer Research: Royal Cancer Hospital Materials and methods for stratifying and treating cancers
CN107714719A (zh) * 2017-11-08 2018-02-23 上海市第妇婴保健院 雷帕霉素在制备治疗白细胞介素‑27低表达子宫内膜癌的药物中的应用
CN111394462A (zh) * 2020-04-13 2020-07-10 浙江大学 一种肝癌索拉非尼耐药circRNA标志物及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856094A (en) * 1995-05-12 1999-01-05 The Johns Hopkins University School Of Medicine Method of detection of neoplastic cells
US5989885A (en) * 1997-01-10 1999-11-23 Myriad Genetics, Inc. Specific mutations of map kinase 4 (MKK4) in human tumor cell lines identify it as a tumor suppressor in various types of cancer
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
US20080063639A1 (en) * 2002-01-18 2008-03-13 Pierre Fabre Medicament Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies
US20080193445A1 (en) * 2002-01-18 2008-08-14 Liliane Goetsch Novel anti-IGF-IR antibodies and uses thereof
US7553485B2 (en) * 2002-01-18 2009-06-30 Pierre Fabre Medicament Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
WO2003100008A2 (en) * 2002-05-24 2003-12-04 Schering Corporation Neutralizing human anti-igfr antibody
JP4473257B2 (ja) * 2003-04-02 2010-06-02 エフ．ホフマン−ラ ロシュ アーゲー インスリン様成長因子ｉ受容体に対する抗体及びその使用
BRPI0417302A (pt) * 2003-12-05 2007-03-06 Compound Therapeutics Inc inibidores de receptores de fator de crescimento endotelial vascular do tipo 2
PT1828249E (pt) * 2004-12-03 2011-02-25 Schering Corp Biomarcadores para a pré-selecção de pacientes para terapêutica anti-igf1r
NZ561648A (en) * 2005-04-15 2009-11-27 Schering Corp Methods and composition of IGF1R inhibitors for treating or preventing cancer
ES2374450T3 (es) * 2005-09-20 2012-02-16 OSI Pharmaceuticals, LLC Marcadores biológicos predictivos de respuesta anticancerígena para inhibidores de cinasa del receptor del factor de crecimiento 1 similar a insulina.
US7875274B2 (en) * 2005-12-16 2011-01-25 The Board Of Trustees Of The Leland Stanford Junior University Protein modulators of resistance to alkylating agents
US20080112888A1 (en) * 2006-06-30 2008-05-15 Schering Corporation Igfbp2 biomarker
NZ578329A (en) * 2006-12-13 2012-05-25 Schering Corp Igf1r inhibitors for treating cancer
EP2145021A2 (en) * 2007-05-17 2010-01-20 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators

Also Published As

Publication number Publication date
WO2009079587A3 (en) 2009-11-12
US20110091524A1 (en) 2011-04-21
WO2009079587A2 (en) 2009-06-25
JP2011505873A (ja) 2011-03-03
EP2247757A2 (en) 2010-11-10
CA2709827A1 (en) 2009-06-25
JP2013078341A (ja) 2013-05-02

Similar Documents

Publication Publication Date Title
MX2010006854A (es) Biomarcadores para sensibilidad a terapia anti-receptor-1 del factor de crecimiento tipo insulina.
PH12021550758A1 (en) The use of inhibitors of bruton`s tyrosine kinase (btk)
WO2010017515A3 (en) Breast cancer specific markers and methods of use
WO2013009655A3 (en) Uses of labeled hsp90 inhibitors
GB2463401B (en) Characterizing prostate disorders by analysis of microvesicles
MX2013002084A (es) Biomarcadores y metodos de tratamiento.
AU2011260390A8 (en) Means and methods for diagnosing pancreatic cancer in a subject
WO2008103645A8 (en) Prostate cancer and melanoma antigens
MX2012004258A (es) Inhibidores de la tirosina quinasa de bruton.
HK1108284A1 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
GB2467467C (en) TAZ/WWTR1 for diagnosis and treatment of cancer
MX2010008496A (es) Metodo para la determinacion de sensibilidad a agente anticancerigeno.
HK1145342A1 (en) Prognosis prediction for melanoma cancer
WO2011015602A3 (en) Lung cancer biomarkers
TW200639404A (en) Method of assessing the effectiveness of a treatment regimen
MX2012003997A (es) Biomarcadores para predecir la sensibilidad y respuesta de enfermedades mediadas por proteina cinasa ck2 a inhibidores de ck2.
MX2013011431A (es) Metodos para predecir y mejorar la supervivencia de pacientes con cancer gastrico.
EA201171178A1 (ru) Устройство и способ для определения и количественного анализа аналитов, в частности, микотоксинов
GB2480980A (en) Methods for predicting cancer response to EGFR inhibitors
MY155340A (en) Use of cathepsin c
MX2012000509A (es) Biomarcador para seleccionar pacientes y metodos relacionados.
GB2465907A (en) VHZ for diagnosis and treatment of cancer
WO2011011453A3 (en) Phenotyping tumor-infiltrating leukocytes
WO2007081777A3 (en) METHODS FOR ACCURATELY MEASURING FREE IgE IN THE PRESENCE OF AN ANTI-IgE THERAPEUTIC
MX2010001582A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.

Legal Events

Date Code Title Description
HC Change of company name or juridical status